Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer
A recent press release showed positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer. The trial, in the 1st-line maintenance setting, compared Lynparza (olaparib) added to standard-of-care Avastin (bevacizumab) vs. Avastin alone in women with or without BRCA gene mutations.
PAOLA-1 met its primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival.
Lynparza is currently approved as 1st-line maintenance treatment of platinum sensitive BRCA-mutated advanced ovarian cancer. Eric Pujade-Lauraine, Medical Director of ARCAGY Research, said, “By studying Lynparza in this broader patient population, we have learned more about how it may help even more patients with advanced ovarian cancer in the future.”
No comments:
Post a Comment